A Phase II Study with Antioxidants, both in the Diet and Supplemented, Pharmaco-Nutritional Support, Progestagen and Anti-COX-2 Showing Efficacy and Safety in Patients with Cancer-Related Anorexia-Cachexia and Oxidative Stress

  • Giovanni Mantovani
  • Clelia Madeddu
  • Antonio Macciò
  • Giulia Gramignano
  • Maria Rita Lusso
  • Elena Massa
  • Giorgio Astara
  • Roberto Serpe


Cancer-related anorexia-cachexia syndrome (CACS) is a complex syndrome characterised by progressive weight loss with depletion of host reserves of skeletal muscle and, to a lesser extent, adipose tissue, anorexia, reduced food intake, poor performance status and quality of life that often precedes death [1]. At the time of diagnosis, 80% of patients with upper gastrointestinal cancers and 60% with lung cancer have already experienced substantial weight loss [2]. The prevalence of cachexia increases from 50 to > 80% before death and in > 20% cachexia is the main cause of death [2]. CACS results from the interaction of the host and the tumour. However, its nature is incompletely understood [3] [6], including the dynamics of host response (activation of systemic inflammatory response, metabolic, immune and neuroendocrine changes) and those tumour characteristics or tumour-derived products that influence expression of the syndrome (e.g. proteolysis-inducing factor, PIF).


Grip Strength Lean Body Mass Cancer Cachexia Medroxyprogesterone Acetate ECOG Performance Status 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Dewys WD, Begg C, Lavin PT et al (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am JMed 69:491–497Google Scholar
  2. 2.
    Bruera E (1997) ABC of palliative care. Anorexia, cachexia, and nutrition. BMJ 315:1219–1222PubMedGoogle Scholar
  3. 3.
    Inui A (2002) Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin 52:72–91PubMedCrossRefGoogle Scholar
  4. 4.
    Crown AL, Cottle K, Lightman SL et al (2002) What is the role of the insulin-like growth factor system in the pathophysiology of cancer cachexia, and how is it regulated? Clin Endocrinol (Oxf) 56:723–733CrossRefGoogle Scholar
  5. 5.
    Brink M, Anwar A, Delafontaine P (2002) Neurohormonal factors in the development of catabolic/anabolic imbalance and cachexia. Int J Cardiol 85:111–121; discussion 121–124PubMedCrossRefGoogle Scholar
  6. 6.
    Heber D, Byerley LO, Tchekmedyian NS (1992) Hormonal and metabolic abnormalities in the malnourished cancer patient: effects on host-tumor interaction. JPEN J Parenter Enterai Nutr 16:60S–64SGoogle Scholar
  7. 7.
    Moldawer LL, Gelin J, Schersten T, Lundholm KG (1987) Circulating interleukin 1 and tumor necrosis factor during inflammation. Am J Physiol 253:R922–R928PubMedGoogle Scholar
  8. 8.
    Strassmann G, Fong M, Kenney JS, Jacob CO (1992) Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 89:1681–1684PubMedCrossRefGoogle Scholar
  9. 9.
    Busbridge J, Dascombe MJ, Hoopkins S (1989) Acute central effects of interleukin-6 on body temperature, thermogenesis and food intake in the rat. Proc Nutr Soc 38:48AGoogle Scholar
  10. 10.
    Gelin J, Moldawer LL, Lonnroth C et al (1991) Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res 51:415–421PubMedGoogle Scholar
  11. 11.
    McLaughlin CL, Rogan GJ, Tou J et al (1992) Food intake and body temperature responses of rats to recombinant human interleukin-1 beta and a tripeptide interleukin-1 beta antagonist. Physiol Behav 52:1155–1160PubMedCrossRefGoogle Scholar
  12. 12.
    Mantovani G, Macciò A, Lai P et al (1998) Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate. Semin Oncol 25:45–52PubMedGoogle Scholar
  13. 13.
    Malmberg KJ, Lenkei R, Petersson M et al (2002) A short-term dietary supplementation of high doses of vitamin E increases T helper 1 cytokine production in patients with advanced colorectal cancer. Clin Cancer Res 8:1772–1778PubMedGoogle Scholar
  14. 14.
    Kono K, Salazar-Onfray F, Petersson M et al (1996) Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T celland natural killer cell-mediated cytotoxicity. Eur J Immunol 26:1308–1313PubMedCrossRefGoogle Scholar
  15. 15.
    Aoe T, Okamoto Y, Saito T (1995) Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. J Exp Med 181:1881–1886PubMedCrossRefGoogle Scholar
  16. 16.
    Otjuji M, Kimura Y, Aoe T et al (1996) Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 e chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci USA 93:13119–13124CrossRefGoogle Scholar
  17. 17.
    Bingisser RM, Tilbrook PA, Holt PG, Kees UR (1998) Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol 160:5729–5734PubMedGoogle Scholar
  18. 18.
    Weijl NI, Cleton FJ, Osanto S (1997) Free radicals and antioxidants in chemotherapy-induced toxicity. Cancer Treat Rev 23:209–240PubMedCrossRefGoogle Scholar
  19. 19.
    Sabitha KE, Shyamaladevi CS (1999) Oxidant and antioxidant activity changes in patients with oral cancer and treated with radiotherapy. Oral Oncol 35:273–277PubMedCrossRefGoogle Scholar
  20. 20.
    Buck M, Chojkier M (1996) Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. EMBO J 15:1753–1765PubMedGoogle Scholar
  21. 21.
    Tisdale MJ (2001) Loss of skeletal muscle in cancer: biochemical mechanisms. Front Biosci 6:D164–D174Google Scholar
  22. 22.
    Shaw JH, Wolfe RR (1987) Glucose and urea kinetics in patients with early and advanced gastrointestinal cancer: the response to glucose infusion, parenteral feeding, and surgical resection. Surgery 101:181–191PubMedGoogle Scholar
  23. 23.
    Tayek JA (1992) A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J Am Coll Nutr 11:445–456PubMedGoogle Scholar
  24. 24.
    Wilmore DW, Aulick LH (1978) Metabolic changes in burned patients. Surg Clin North Am 58:1173–1187PubMedGoogle Scholar
  25. 25.
    Roth E, Mühlbacher F, Rauhs R et al (1982) Metabolic disorders in severe abdominal sepsis: glutamine deficiency in skeletal muscle. Clin Nutr 1:25–41PubMedCrossRefGoogle Scholar
  26. 26.
    Mantovani G, Macciò A, Madeddu C et al (2002) Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status. Int J Cancer 98:84–91PubMedCrossRefGoogle Scholar
  27. 27.
    Mantovani G, Macciò A, Madeddu C et al (2003) The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression. Free Radic Res 37:213–223PubMedCrossRefGoogle Scholar
  28. 28.
    Mantovani G, Macciò A, Mura L et al (2000) Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med 78:554–561PubMedCrossRefGoogle Scholar
  29. 29.
    Mantovani G, Macciò A, Madeddu C et al (2001) Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites. J Mol Med 79:406–414PubMedCrossRefGoogle Scholar
  30. 30.
    Mantovani G, Macciò A, Melis G et al (2000) Restoration of functional defects in peripheral blood mononuclear cells isolated from cancer patients by thiol antioxidants alpha-lipoic acid and N-acetyl cysteine. Int J Cancer 86:842–847PubMedCrossRefGoogle Scholar
  31. 31.
    Mantovani G, Madeddu C, Macciò A et al (2004) Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment. Cancer Epidemiol Biomarkers Prev 13:1651–1659PubMedGoogle Scholar
  32. 32.
    Mantovani G, Maccio A, Madeddu C et al (2006) A Phase II study with antioxidants, both in the diet and supplemented, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia (CACS) and oxidative stress (OS). Cancer Epidemiol Biomarkers Prev 15:1030–1034PubMedCrossRefGoogle Scholar
  33. 33.
    Higdon JV, Frei B (2003) Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 43:89–143PubMedCrossRefGoogle Scholar
  34. 34.
    Mantovani G, Macciò A, Esu S et al (1997) Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Eur J Cancer 33:602–607PubMedCrossRefGoogle Scholar
  35. 35.
    Cerchietti LC, Navigante AH, Peluffo GD et al (2004) Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study. J Pain Symptom Manage 27:85–95PubMedCrossRefGoogle Scholar
  36. 36.
    Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
  37. 37.
    Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655PubMedCrossRefGoogle Scholar
  38. 38.
    Stein KD, Martin SC, Hann DM, Jacobsen PB (1998) A multidimensional measure of fatigue for use with cancer patients. Cancer Pract 6:143–152PubMedCrossRefGoogle Scholar
  39. 39.
    Alberti A, Bolognini L, Macciantelli D, Caratelli M (2000) The radical cation of N,N-diethyl-paraphenylendiamine: a possible indicator of oxidative stress in biological samples. Res Chem Intermed 26:253–267Google Scholar
  40. 40.
    Mantovani G, Macciò A, Massa E, Madeddu C (2001) Managing cancer-related anorexia/cachexia. Drugs 61:499–514PubMedCrossRefGoogle Scholar
  41. 41.
    Laviano A, Meguid MM (1996) Nutritional issues in cancer management. Nutrition 12:358–371PubMedCrossRefGoogle Scholar
  42. 42.
    Klein S, Kinney J, Jeejeebhoy K et al (1997) Nutrition support in clinical practice: review of published data and recommendations for future research directions. Summary of a conference sponsored by the National Institutes of Health, American Society for Parenteral and Enterai Nutrition, and American Society for Clinical Nutrition. Am J Clin Nutr 66:683–706PubMedGoogle Scholar
  43. 43.
    Sikora SS, Ribeiro U, Kane JM3rd et al (1998) Role of nutrition support during induction chemoradiation therapy in esophageal cancer. JPEN J Parenter Enterai Nutr 22:18–21Google Scholar
  44. 44.
    Lipman TO (1991) Clinical trials of nutritional support in cancer. Parenteral and enterai therapy. Hematol Oncol Clin North Am 5:91–102PubMedGoogle Scholar
  45. 45.
    Wigmore S, Fearon, KC, Maingay JP, Ross JA (1999) Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci (Lond) 92:215–221Google Scholar
  46. 46.
    Tisdale MJ (2004) Cancer cachexia. Langenbecks Arch Surg 389:299–305PubMedCrossRefGoogle Scholar
  47. 47.
    Lazarus D, Destree AT, Mazzola LM et al (1999) A new model of cancer cachexia: contribution of the ubiquitin-proteasome pathway. Am J Physiol 277(2 Pt 1):E332–E341PubMedGoogle Scholar
  48. 48.
    Whitehouse AS, Tisdale MJ (2003) Increased expression of the ubiquitin-proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-kappaB. Br J Cancer 89:1116–1122PubMedCrossRefGoogle Scholar
  49. 49.
    Barber MD, Preston T, McMillan DC et al (2004) Modulation of the liver export protein synthetic response to feeding by an n-3 fatty-acid-enriched nutritional supplement is associated with anabolism in cachectic cancer patients. Clin Sci (Lond) 106:359–364CrossRefGoogle Scholar
  50. 50.
    Togni V, Ota CC, Folador A et al (2003) Cancer cachexia and tumor growth reduction in Walker 256 tumor-bearing rats supplemented with N-3 polyunsaturated fatty acids for one generation. Nutr Cancer 46:52–58PubMedCrossRefGoogle Scholar
  51. 51.
    Jho DH, Babcock TA, Tevar R et al (2002) Eicosapentaenoic acid supplementation reduces tumor volume and attenuates cachexia in a rat model of progressive non-metastasizing malignancy. JPEN J Parenter Enterai Nutr 26:291–297Google Scholar
  52. 52.
    Hardman WE, Moyer MP, Cameron IL (2002) Consumption of an omega-3 fatty acids product, INCELL AAFA, reduced side-effects of CPT-11 (irinotecan) in mice. Br J Cancer 86:983–988PubMedCrossRefGoogle Scholar
  53. 53.
    Hardman WE (2002) Omega-3 fatty acids to augment cancer therapy. J Nutr 132:3508S–3512SPubMedGoogle Scholar
  54. 54.
    Barber MD, Fearon KC (2001) Tolerance and incorporation of a high-dose eicosapentaenoic acid diester emulsion by patients with pancreatic cancer cachexia. Lipids 36:347–351PubMedCrossRefGoogle Scholar
  55. 55.
    Wigmore SJ, Barber MD, Ross JA et al (2000) Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer 36:177–184PubMedCrossRefGoogle Scholar
  56. 56.
    Fearon KC, Von Meyenfeldt MF, Moses AG et al (2003) Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 52:1479–1486PubMedCrossRefGoogle Scholar
  57. 57.
    Moses AW, Slater C, Preston T et al (2004) Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 90:996–1002PubMedCrossRefGoogle Scholar
  58. 58.
    Ferrando AA, Stuart CA, Sheffield-Moore M, Wolfe RR (1999) Inactivity amplifies the catabolic response of skeletal muscle to cortisol. J Clin Endocrinol Metab 84:3515–3521PubMedCrossRefGoogle Scholar
  59. 59.
    Jatoi ARK, Rowland K, Loprinzi CL et al (2003) An eicosapentaenoic acid (EPA)-enriched supplement versus megestrol acetate (MA) versus both for patients with cancer-associated wasting. A collaborative effort from the North Central Cancer Treatment Group (NCCTG) and the National Cancer Institute of Canada. Proc Am Soc Clin Oncol 22: 743 (abs 2987)Google Scholar
  60. 60.
    Downer S, Joel S, Allbright A et al (1993) A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia. Br J Cancer 67:1102–1105PubMedGoogle Scholar
  61. 61.
    Simons JP, Aaronson NK, Vansteenkiste JF et al (1996) Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advancedstage non-hormone-sensitive cancer: a placebo-controlled multicenter study. J Clin Oncol 14:1077–1084PubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2006

Authors and Affiliations

  • Giovanni Mantovani
    • 1
  • Clelia Madeddu
    • 1
  • Antonio Macciò
    • 1
  • Giulia Gramignano
    • 1
  • Maria Rita Lusso
    • 1
  • Elena Massa
    • 1
  • Giorgio Astara
    • 1
  • Roberto Serpe
    • 1
  1. 1.Department of Medical OncologyUniversity of CagliariCagliariItaly

Personalised recommendations